Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.
Fujifilm Irvine Scientific announced on Sept. 29, 2020 that it has become a worldwide distributor of cellnest, a recombinant peptide attachment substrate for optimal adhesion and proliferation of stem cells in chemically defined, animal-component-free conditions.
Designed and manufactured by Fujifilm Corporation, cellnest can work in conjunction with any adherent cell type that attaches to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that facilitates cell binding, a company press release said. Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.
“We are dedicated to accelerating the development and introduction of new offerings, including cellnest, to support our partners in advancing cell and gene therapy research,” said Yutaka Yamaguchi, general manager, Life Science Strategic Business Office, Fujifilm Holdings America Corporation, and chairman and CEO, Fujifilm Irvine Scientific, in the press release. “Leveraging the collective expertise and capabilities of our resources within the network of Fujifilm life science companies, enables us to provide innovative solutions for our partners, from discovery through to commercialization.”
Source: Fujifilm Irvine Scientific
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.